scholarly journals Development and Evaluation of a Real-World Outcomes-Based Tool to Support Informed Clinical Decision Making in the Palliative Treatment of Patients With Metastatic NSCLC

2021 ◽  
pp. 570-578
Author(s):  
Christine M. Cramer-van der Welle ◽  
Elisabeth A. Kastelijn ◽  
Bram C. Plouvier ◽  
Cornelia F. van Uden-Kraan ◽  
Franz M. N. H. Schramel ◽  
...  

PURPOSE To develop and evaluate a tool for patients with stage IV non–small-cell lung cancer and their thoracic oncologists (TOs) that provides insight into real-world effectiveness of systemic treatments to support informed clinical decision making in the palliative setting. METHODS A participatory design approach was used to acquire insights from patients and TOs into preferences regarding the content and design of the web-based tool. Implementation was investigated by means of an adoption and usage rate. The appreciation of the tool was evaluated through a telephone survey with patients and a questionnaire for TOs. RESULTS From clinical data of 2,989 patients with stage IV non–small-cell lung cancer diagnosed in one of the Santeon hospitals, an interface was developed to show treatments plus both real-world outcomes and clinical trial results after selecting patient characteristics (patients like me). This prototype of the tool was finalized after discussion in a focus group with four TOs and semi-structured interviews with six patients. The tool was implemented and used by TOs in three of six Santeon hospitals (50% adoption rate). The tool was used in 48 patients (29% usage rate), of which 17 participated in the telephone survey. Ten TOs responded to the questionnaire. The responses varied from positive reactions on the clear overview of treatment outcomes to statements that the tool rarely changed treatment decisions. Overall, the majority of patients and TOs scored the tool as of added value (71% and 83%, respectively). CONCLUSION Our real-world data tool in metastatic lung cancer was appreciated in clinical practice by both patients and TOs. However, the efficacy of the implementation can be improved.

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
S. Mokhles ◽  
J. J. M. E. Nuyttens ◽  
M. de Mol ◽  
J. G. J. V. Aerts ◽  
A. P. W. M. Maat ◽  
...  

Lung Cancer ◽  
2015 ◽  
Vol 90 (3) ◽  
pp. 465-471 ◽  
Author(s):  
Maximilian von Laffert ◽  
Albrecht Stenzinger ◽  
Michael Hummel ◽  
Wilko Weichert ◽  
Dido Lenze ◽  
...  

2017 ◽  
Vol 13 (4) ◽  
pp. e346-e352 ◽  
Author(s):  
David M. Jackman ◽  
Yichen Zhang ◽  
Carole Dalby ◽  
Tom Nguyen ◽  
Julia Nagle ◽  
...  

Purpose: Increasing costs and medical complexity are significant challenges in modern oncology. We explored the use of clinical pathways to support clinical decision making and manage resources prospectively across our network. Materials and Methods: We created customized lung cancer pathways and partnered with a commercial vendor to provide a Web-based platform for real-time decision support and post-treatment data aggregation. Dana-Farber Cancer Institute (DFCI) Pathways for non–small cell lung cancer (NSCLC) were introduced in January 2014. We identified all DFCI patients who were diagnosed and treated for stage IV NSCLC in 2012 (before pathways) and 2014 (after pathways). Costs of care were determined for 1 year from the time of diagnosis. Results: Pre- and postpathway cohorts included 160 and 210 patients with stage IV NSCLC, respectively. The prepathway group had more women but was otherwise similarly matched for demographic and tumor characteristics. The total 12-month cost of care (adjusted for age, sex, race, distance to DFCI, clinical trial enrollment, and EGFR and ALK status) demonstrated a $15,013 savings after the implementation of pathways ($67,050 before pathways v $52,037 after pathways). Antineoplastics were the largest source of cost savings. Clinical outcomes were not compromised, with similar median overall survival times (10.7 months before v 11.2 months after pathways; P = .08). Conclusion: After introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly, with no compromise in survival. In an era where comparative outcomes analysis and value assessment are increasingly important, the implementation of clinical pathways may provide a means to coalesce and disseminate institutional expertise and track and learn from care decisions.


2019 ◽  
Vol 14 (10) ◽  
pp. S307-S308
Author(s):  
K. Kerrigan ◽  
B. Haaland ◽  
B. Adamson ◽  
S. Patel ◽  
W. Akerley

2021 ◽  
Vol 16 (3) ◽  
pp. S693
Author(s):  
A. Gibson ◽  
R. Tudor ◽  
M. Dean ◽  
A. Elegbede ◽  
A. D'Silva ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document